Dr Ana Arance talks to ecancer about the updated findings of LEAP-004, Lenvatinib (LEN) plus pembrolizumab (pembro) for patients (pts) with advanced melanoma and confirmed progression on a PD-1 or PD-L1 Inhibitor.
She begins by explaining that this phase II trial is a single arm international study with 103 patients and is the largest trial in this setting with patients with advanced metastatic melanoma.
Dr Arance then goes on to say within this trial 60% of patients fulfilled the category of primary resistance while the rest fulfilled the definition of secondary resistance. She notes that the response rate is the same in the context of primary resistance (22.6%) and secondary resistance (22.7%) showing that this treatment can have activity in both settings.
Dr Arance concludes by pointing out that this is a tough to treat group of melanoma patients as approximately 58% have received 2 or more lines of prior therapy and the objective response rate is 21.4%. For future development there is the LEAP-003 trial that is testing the efficacy of this combination as first-line treatment.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.